Products
Our initial candidate treats dystrophies that cause corneal blindness.
In Japan, early clinical research1 followed by dose ranging and confirmatory clinical trials have successfully demonstrated safety, efficacy, and tolerability of our lead product candidate. We have received regulatory approval from Japan’s PMDA.
In the US, we are preparing to initiate clinical trials, with additional clinical development plans under way in the EU.
